Q2 Solutions
Q2 Solutions is recorded as a service provider in 631 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 631 trials · Latest update first
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
Sponsor Atea Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- A global amendment increased the planned eligible sample from 1500 to approximately 2510 because low global COVID-19 hospitalization and death rates reduced endpoint event rates.
- Rapid enrollment prevented the planned interim analysis after 65% of subjects completed Day 29 assessments; consequently, adolescent enrollment was not recommended and no pediatric subjects were enrolled.
- Of 218 screen failures, 177 were due to failure to meet entry criteria.
- Enrollment was concentrated in North America (1811/2285 subjects), whereas Europe enrolled 57 subjects, Asia 170 subjects, and other countries 247 subjects.
These findings describe the trial, not the service provider’s performance or responsibility.
A Non-Randomized, Open-Label, Non-Controlled, Adaptive, Multiple-Dose Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Zosurabalpin Following Intravenous Administration In Healthy Participants
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 35 healthy subjects at one investigative site in the Netherlands between 18 October 2023 and 28 March 2024.
- All subjects in the 1500 mg/Q12h cohort discontinued before Day 10, precluding Day 10 pharmacokinetic assessments for this cohort.
- A protocol amendment added ultrasound inspection at follow-up after PICC-line removal to monitor safety and well-being.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures
Sponsor Sk Life Science Inc.
- Start (EU)
- Latest update
- Estimated end
17 β-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with Nonalcoholic Steatohepatitis
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Sponsor BeOne Medicines I GmbH
- Start (EU)
- Latest update
- Estimated end
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Participants were recruited at 26 investigative sites across 11 countries from 09 March 2022 to 09 April 2026.
- One participant was randomized in error, was not treated, and was excluded from the presented results.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination with BNT116 (FixVac Lung) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination with Chemotherapy versus Cemiplimab in Combination with Chemotherapy in Patients with Resectable Early Stage (Stage II to IIIB [N2]) NSCLC
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination with Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn’s Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Q2 Solutions?
The 2026-10-09 snapshot links Q2 Solutions to 631 distinct CTIS trials. Recorded services include Laboratory services, Cardiac services, Bioanalytical testing, Clinical monitoring, among 196 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Q2 Solutions?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Immunology, Haematological Malignancies, Neurology. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Q2 Solutions conducted?
The linked trials record locations in 27 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Q2 Solutions delivered services.
What can this page tell me about Q2 Solutions's trial experience?
Browse 631 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 26 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 17 recorded name variants under Q2 Solutions. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Q Squared Solutions
- Q Squared Solutions (Beijing) Co. Ltd.
- Q Squared Solutions (Quest) LLC
- Q Squared Solutions BioSciences LLC
- Q Squared Solutions Holdings LLC
- Q Squared Solutions LLC
- Q Squared Solutions LLC.
- Q Squared Solutions Limited
- Q2 Solutions
- Q2 Solutions - Innovation Labs
- Q2 Solutions BioSciences
- Q2 Solutions Central Laboratories
- Q2 Solutions Kk
- Q2 Solutions LLC
- Q2 Solutions Ltd.
- Q2 Solutions Singapore
- Q2 Solutions – Partner Laboratory